“A Differentiated, Asia-Centric Approach to Global Clinical Development Challenges”
Jigsaw Clinical Research Solutions is pleased to announce that we have a full range of PPE including Masks and Gloves that meet all required specifications and certifications (CE, FDA, ISO etc.) for sale globally. In addition, as a response to the latest published data on airborne transmission of COVID-19 we have Air Purification Systems in various configurations available.
Contact us for details, pricing, and availability at firstname.lastname@example.org or me directly at email@example.com
Adept in providing support and management for all Clinical Trial Phases, Jigsaw is also active in generic and biosimilar drug development.
Jigsaw has additional service capabilities including Preclinical Analysis, Biostatistics, Pharmacovigilance, and Data Management. Utilizing a unique Strategic Partnership strategy with best-in-class functional service providers and in-house project management expertise, Jigsaw is able to provide solutions to meet the requirements of any sponsor.
Cost. Quality. Efficiency.
Preclinical to Post-Marketing
Pharmacovigilance and Data Management
Best-In-Class Systems and Support
Training & Education
Passionate Educators; Dynamic Team
Preclinical and Clinical Laboratory
Singapore Bioimaging Consortium (SBIC) - Imaging and Food Adulteration/Contamination Testing
Malvern PA., USA
AWINSA Life Sciences
New Delhi, India
Pharmacovigilance and Drug Safety
Contract Research & Contract Sales Organization
Clinical Research Malaysia Bestows its Industry Recognition Award to Jeffrey Scott Yablon
Jeffrey Scott Yablon has received an Industry Recognition Award from Clinical Research Malaysia for his outstanding efforts in promoting Malaysia as a preferred destination for Industry Sponsored Research (ISR).
“I’m honored to have been recognized by Clinical Research Malaysia with this award,” said Yablon. “Expanding business in Malaysia has opened up multiple opportunities for many. Malaysia offers unique benefits to the clinical research industry, and I’m truly honored to have been recognized for my efforts on behalf of the region.”
Yablon was recognized for his dual efforts in promoting clinical research in Malaysia and developing the clinical research ecosystem in the country.
Strategic Alliance Between Tranz-Life, Pakistan & Jigsaw Clinical Research Solutions, Malaysia
KUALA LUMPUR, DEC 17 -- Tranz-Life Pvt. and Jigsaw Clinical Research Solutions Sdn Bhd (JCRS) have entered into a strategic alliance where both organizations will collaborate in the provision of Clinical Research Services for the Pakistan and Bangladesh markets. These services include Clinical Trial Management, Laboratory Analysis, Medical Writing, and BA/BE studies. Both organizations have also made a commitment to provide local training on GCP, Clinical Trial Management, and Principal Investigator skills.
Tranz-Life (Pvt.) Ltd. is a Contract Commercial Organization, with expertise, experience and innovation to deliver business impact. It collaborates with both local and multinational enterprises for contract sales, patient support groups and clinical development programs.
In partnership with JCRS, Tranz-Life will now increase its focus on clinical trial management for clinical programs in
Phase III – Phase IV.
Observational Research/studies & Registries
This encompasses all aspects of the clinical program, including site management, clinical operations, pharmacovigilance and drug safety, and clinical technology management.
JCRS is a Service Provider and Contract Research Organization (CRO) focused on delivering efficient, cost effective solutions for the regional clinical research market. From their base of operations in Kuala Lumpur, Malaysia, JCRS functions as an integrator and driver of the development process. JCRS manages multiple complexities on behalf of its clients, and is involved in the development of generics and biosimilars, with additional capabilities in biostatistics, data management, and early-phase clinical research. Partnering with fully accredited facilities throughout Asia, and through the experience of its management team, JCRS is able to customize solutions to meet the requirements of any sponsor.
Shamsul Islam managing director of Tranz-Life stated, “We are excited to enter into a strategic alliance with Jigsaw. This collaboration will act as an enabler for the local healthcare industry to develop technological learning, enhance creative insights and increase capacity building from the expertise of JCRS, particularly export potential. We are hopeful that this partnership will not only bring investment into Pakistan and scale-up institutional strategies and capacities. It will also help local industry to redesign their business models, address challenges, develop creative solutions and find new revenue streams to foster sustained and impactful outcomes to their business.”
According to Jeffrey Scott Yablon President and CEO of Jigsaw, “This collaboration will enable both organizations to bring best in class clinical research services directly to the markets served. We believe that the combined strength of both companies will set a high standard for clinical research”.
Jigsaw Clinical Research Solutions & SBIC Enter Into Strategic Partnership
Kuala Lumpur, Malaysia / Hyderabad, India / Singapore
Jigsaw Clinical Research Solutions (Jigsaw) and the Singapore Bioimaging Consortium (SBIC) have entered into a collaborative agreement, to support the pharmaceutical and biotechnology industries, and the food and beverage production industry in product testing and development. Jigsaw and SBIC will tap on their capabilities in business development and advanced imaging modalities respectively, to provide analytical, clinical, pre-clinical services for drug discovery trials and food testing.
The use of imaging in medical research and clinical trials is rapidly increasing, particularly in Asia. The global market for such services is expected to be in excess of USD 1 billion by 20211. In addition, imaging modalities such as Nuclear Magnetic Resonance (NMR) in food screening for quality, safety, counterfeiting, and adulteration, is fast becoming a key testing standard across the globe.
Under the agreement, Jigsaw will promote SBIC’s imaging capabilities globally, especially in the area of magnetic resonance imaging (MRI) and spectroscopy, nuclear imaging, and optical imaging, for food screening and drug discovery trials. SBIC will focus on multiple therapeutic areas such as oncology, metabolism, neurological, and cardiovascular diseases.
Vimta Labs, a provider of clinical research and developmental services to global pharmaceutical & biotechnology companies, and a principal contracted strategic partner of Jigsaw, will also work with SBIC to employ cutting-edge imaging and analytical readouts, to support the needs of the life sciences, pharmaceutical and food and beverage industries.
Jigsaw will also extend consulting support for the development of SBIC’s Imaging Core Lab Services, a platform for the analysis and management of pre-clinical and clinical imaging trial data. The Imaging Core Lab Services will produce reliable quantitative, semi-quantitative, and qualitative endpoints that can be used to assess disease status and drug effects, in compliance with regulations set by global drug regulators, as well as industrial standards for Contract Research Organizations (CROs). The lab’s initial focus will be on Neuro and Metabolic MR/Optical Imaging, and it plans to develop capabilities to support therapeutic areas such as cardiovascular disease, and oncology.
Mr. Jeffrey Scott Yablon, President and CEO of Jigsaw stated, “This is a mutually beneficialcollaborative arrangement between Jigsaw, Vimta Labs, and SBIC to further commercial development of several SBIC initiatives. Jigsaw looks forward to supporting SBIC in charting theirfuture success”
Mr. Sreenivas Neerukonda, Sr. Vice President & Global Head Business Development of Vimta stated, “Vimta’s team is excited to partner with SBIC and Jigsaw, and be part of thescientific integrated research ecosystem”.
According to Prof Patrick Cozzone, Executive Director of SBIC, “this partnership leveragesSBIC’s advanced capabilities in pre-clinical and clinical imaging, allowing Singapore to enter exciting new domains in the food and consumer industries. Our strategic collaboration with Jigsaw and Vimta Labs also provides the region with a distinct competitive advantage across scientific/deep-tech R&D and commercial business development to address the needs of the fast-growing, high-value biomedical sector.”
For additional information and enquiries contact:
Jigsaw Clinical Research Solutions, Malaysia:
Mr. George Zachariah, Chief Operating Officer
Vimta Labs, India:
Mr. Satya Sreenivas Neerukonda, VP/Global BD Head
SBIC, A*Star, Singapore:
Dr. Sakthivel Sekar, Principal BDM/PMO
Ms Lynn Hong, Corporate Communications
JCRS Speaks at the New Drug Advancement Association, Innovative Drug Forum In Beijing on the “The Benefit of Conducting Clinical Trials In ASEAN and India"
Let Us Help You Put The Pieces Together
11A Lorong Kurau, 59100
Bangsar, Kuala Lumpur, Malaysia
+6012 299 2459